Home › Lipoid Nephrosis › Michigan
Lipoid Nephrosis clinical trials in Michigan
5 studies for Lipoid Nephrosis are looking for participants at sites in Michigan.
Cities in Michigan
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- University of Michigan Health System - Ann Arbor- Site Number : 8400010, Ann Arbor
RecruitingPhase 2
Ages 16 to 75 · All sexes · Updated Sep 23, 2026 · NCT06500702Nephrotic Syndrome Study Network
- CS Mott Children's Hospital, University of Michigan, Ann Arbor
- University of Michigan Medical Center, Ann Arbor
RecruitingObservational study
Up to age 80 · All sexes · Updated Jun 10, 2026 · NCT01209000Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- C.S. Mott Children's Hospital, Ann Arbor
RecruitingPhase 2
Ages 1 to 17 · All sexes · Updated May 12, 2026 · NCT05003986Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
- University of Michigan, Ann Arbor
RecruitingObservational study
All ages · All sexes · Updated Apr 29, 2026 · NCT05650619Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
- University of Michigan, Ann Arbor
RecruitingObservational study
Ages 2 and older · All sexes · Updated Dec 22, 2025 · NCT05505500From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.